Search results
Found 34 matches for
People with Rheumatoid Arthritis (RA) could soon benefit from a new drug treatment that not only suppresses inflammation but also significantly reduces patient reported pain scores. Otilimab is a monoclonal antibody, biologic drug, which targets and suppresses the inflammatory cytokine GM-CSF.
Health Economics & Outcomes Research
Our research aims to improve people's health and wellbeing by making the most efficient use of health and social care resources. To achieve this, we use real-world data and mathematical models to evaluate the costs and consequences of applying different interventions over a period of time, often the entire lifetime of patients.
Meet Chris
-
Christopher Buckley
Kennedy Professor of Translational Rheumatology and Director of Clinical Research
Funded by
Find out more about
Similar stories
First of its kind study for children with arthritis reveals possible new disease targets
4 July 2025
Researchers have been able to see what happens in the inflamed joints of children with arthritis, giving insight into why treatments affect children differently.